Rongchang Biology (09995.HK) expects a parent company's net profit of approximately 4.7 billion yuan by mid-2026.

According to the Zhitong Finance APP, Rongchang Bio (09995.HK) announced that it expects its operating revenue for the mid-year of 2026 to be approximately RMB 5.85 billion, an increase of about 433% year-on-year. It anticipates a net profit attributable to the owners of the parent company of approximately RMB 4.7 billion for the mid-year of 2026, achieving a turnaround from loss to profit compared to the same period last year.